Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 1;49(W1):W174–W184. doi: 10.1093/nar/gkab438

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Overview of DrugComb data statistics. (A, B) Classifications of cell lines (n = 2320) and drugs (n = 8397). (C) The CSS score for drug combinations is higher than the RI score for monotherapy drugs, suggesting the general rationale for drug combination studies. (D) The correlations of synergy scores. (E) An example of SS plot for vorinostat and sorafenib combination across 128 cell lines. DLD-1 is a colon cancer cell line, which has shown strong synergy and sensitivity to the combination (38). (F) The synergy landscape over the dose-response matrix of vorinostat and sorafenib in DLD-1.